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I. INTRODUCTION 
The majority of Americans support the legalization of marijuana, 
suggesting that future policy will reflect the views of the democratic 
majority.
1
  Polls show that the support of legalizing marijuana is increasing 
over time.
2
  The upward trend of Americans favoring legalization is not a 
recent phenomenon, but a trend that has grown steadily since 1985.
3
  The 
substantial increase in political support for legalizing marijuana does not 
match the minute increase of marijuana users in the United States.
4
  There 
has only been a 5% increase in Americans’ usage of marijuana since 1985, 
which was the turning point of the upward trend in favoring the legalization 
of marijuana.
5
  A 5% increase in marijuana use does not explain a 35% 
change in support for legalization.
6
  Indeed, national polls show that public 
support for the legalization of marijuana is ahead of most elected officials’ 
support.
7
  Nonetheless, marijuana policy reform is occurring throughout the 
United States.
8
 
                                                          
 1.  See Art Swift, For First Time, Americans Favor Legalizing Marijuana, 
GALLUP (Oct. 22, 2013), http://www.gallup.com/poll/165539/first-time-americans-
favor-legalizing-marijuana.aspx (finding that 58% of Americans favor legalizing 
marijuana). 
 2.  See id. (illustrating that support for legalizing of marijuana has risen from 12% 
since 1969 to 58% as of 2013).   
 3.  See id. (showing that 23% of Americans favored legalization of marijuana in 
1985). 
 4.  See Lydia Saad, In U.S., 38% Have Tried Marijuana, Little Changed Since 
‘80s, GALLUP (Aug. 2, 2013), http://www.gallup.com/poll/163835/tried-marijuana-
little-changed-80s.aspx; Swift, supra note 1. 
 5.  See Saad, supra note 4 (displaying marijuana usage change from 33% to 38% 
between 1985 and 2013). 
 6.  See id.; Swift, supra note 1. 
 7.  See MARIJUANA POLICY PROJECT, SUPPORT FOR MARIJUANA POLICY REFORM 1 
(2014) available at http://www.mpp.org/assets/pdfs/library/State-Polling.pdf. 
 8.  See State Marijuana Laws Map, GOVERNING, http://www.governing.com/gov-
2
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Currently, twenty-three states and the District of Columbia have 
legalized possession of marijuana in some form.
9
  As of November 2014, 
Alaska, Oregon, and the District of Columbia have pushed their 
legalization efforts beyond medicinal use joining Colorado and Washington 
in legalizing marijuana for recreational use.
10
  The District of Columbia’s 
recreational marijuana initiative, Initiative 71, took effect on February 26, 
2015.
11
 Colorado is collecting millions of dollars per month in revenue 
from marijuana taxes, fees, and licensing, which may encourage states that 
have legalized medicinal marijuana to legalize recreational marijuana.
12
  
Indeed, 2014 was a substantial year for marijuana legalization efforts.
13
  
However, analysts suggest that multiple more state ballot initiatives are 
likely to follow in the coming years, which could make the legalization of 
marijuana a platform issue in the 2016 presidential election.
14
 
This Comment argues that marijuana could not be regulated under the 
Food and Drug Administration (FDA) drug regime easily, and would rather 
be best regulated under a new Food, Drug, and Cosmetic Act (FDCA) 
statutory section resembling the FDCA’s tobacco section.  Part II examines 
the FDA’s regulatory models that could be used to regulate marijuana.15  
Part III applies marijuana to existing regulatory models.
16
  Part IV 
                                                          
data/state-marijuana-laws-map-medical-recreational.html (last visited Nov. 9, 2014) 
[hereinafter Marijuana Map] (discussing the fact that November 2014 elections 
resulted in Alaska, Oregon, and District of Columbia legalizing recreational 
marijuana). 
 9.  Id. 
 10.  See id.  
 11.  See id. (comparing the 2014 ballot initiatives to Colorado and Washington’s 
ballot initiatives legalizing recreational marijuana in 2012); Press Release, Marijuana 
Prohibition Ends in DC as Initiative 71 Takes Effect, DCMJ (Feb. 26, 2015), available 
at http://dcmj.org/press-release-marijuana-prohibition-ends-dc-initiative-71-takes-
effect/. 
 12.  See Colorado Marijuana Tax Data, COLORADO DEPT. OF REVENUE, 
https://www.colorado.gov/pacific/sites/default/files/0215%20Marijuana%20Tax%2C%
20License%2C%20and%20Fees%20Report.pdf (last visited May 8, 2015) (reporting 
$9 million in state revenue from marijuana for March 2015).  
 13.  See Marijuana Map, supra note 8 (explaining that the number of states 
legalizing recreational marijuana doubled in 2014).  
 14.  See Nick Wing, These States Are Most Likely To Legalize Next. Will You Have 
A Happier 4/20 In 2015?, HUFFINGTON POST (Apr. 18, 2014), 
http://www.huffingtonpost.com/2014/04/18/states-legalize-weed_n_5162737.html (last 
updated Apr. 23, 2014).  
 15.  See infra Part II (outlining the FDA’s regulatory scheme of drugs and 
tobacco).  
 16.  See infra Part III (analyzing marijuana regulation under the FDCA’s drug 
section and tobacco section).  
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concludes that marijuana has the potential to be regulated under either a 
drug model or tobacco model, but that the tobacco model is preferable 
because of its ability to incorporate the recreational use of marijuana and its 
lack of standardization.
17
 
II. BACKGROUND 
A. The FDCA Gives the FDA Vast Regulatory Authority over Food, 
Drugs, Biologics, Dietary Supplements, Tobacco, and Medical Devices 
The FDCA empowers the FDA to exercise national authority in 
regulating food (including dietary supplements), drugs, medical devices, 
tobacco, cosmetics, and biologics.
18
  In giving the FDA broad regulatory 
power with regards to these categories, Congress intended to provide the 
FDA with federally mandated authority.
19
  The FDA is responsible for 
making sure that the regulatory schemes constructed by the FDCA are 
followed, which first requires the product in question be classified under 
one of the FDCA’s definitions such as a cosmetic or supplement.20  After 
the product is classified, it is regulated under the product’s corresponding 
section in the FDCA.
21
 
1. Defining “Drug” 
Congress enacted the FDCA with the intention of it being liberally 
construed and interpreted “as broad as its literal language indicates.”22  The 
FDCA defines “drug” as: 
 
(A) articles recognized in the official United States Pharmacopœia, 
official Homœopathic Pharmacopœia of the United States, or official 
National Formulary, or any supplement to any of them; and (B) articles 
intended for use in the diagnosis, cure, mitigation, treatment, or 
prevention of disease in man or other animals; and (C) articles (other 
than food) intended to affect the structure or any function of the body of 
                                                          
 17.  See infra Part IV (concluding that federal regulation of marijuana is coming 
and its regulation will look more like a tobacco regime than a drug regime). 
 18.  See generally 21 U.S.C. §§ 301-399f (2012) (containing all statutory 
previsions giving FDA regulatory authority). 
 19.  See What does FDA Do?, FDA, http://www.fda.gov/aboutfda/transparency/
basics/ucm194877.htm (last visited Oct. 20, 2014). 
 20.  See § 321 (providing various definitions of products that fall within the FDA’s 
regulatory authority).  
 21.  See, e.g., §§ 341-50 (regulating food); §§ 351-60 (regulating drugs and 
devices); § 387 (regulating tobacco).  
 22.  See United States v. Bacto-Unidisk, 394 U.S. 784, 798 (1969) (stating that 
definition of “drug” within FDCA was meant to be broadly interpreted). 
4
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man or other animals.
23
 
 
However, even if a product is not specifically intended to diagnose, cure, 
mitigate, treat, or prevent a disease; if the manufacturer makes a claim that 
its product can diagnose, cure, mitigate, treat or prevent a disease, then the 
product would be construed as a drug by the FDA.
24
 
2. Defining “New Drug” 
Once a product is determined to be a “drug,” one would have to consider 
whether it is a “new drug.”25  A drug is considered a new drug if it is not 
generally recognized by scientific experts as safe and effective for its 
intended use.
26
  New drugs are prohibited from being introduced into 
commerce until they are deemed safe and effective.
27
  The FDA interprets 
the FDCA to mean that a drug is not generally recognized as safe and 
effective, and thus a “new drug,” if it is marketed without an FDA-
approved New Drug Application (NDA).
28
  The Supreme Court affirmed 
this interpretation of the FDCA and has held that without an approved 
NDA a drug cannot be generally recognized as safe and effective, no matter 
the validity of the claim.
29
  Minus a few narrow exceptions, an approved 
NDA is a required part of a drug being recognized as safe and effective in 
the United States.
30
 
3. The NDA Process 
Prior to submitting an NDA, the sponsor of the NDA must submit an 
                                                          
 23.  See § 321(g)(1). 
 24.  See, e.g., General Mills, Inc. Warning Letter, FDA (May 5, 2009), available at 
http://www.fda.gov/iceci/enforcementactions/warningletters/2009/ucm162943.htm 
(warning the makers of Cheerios® Toasted Whole Grain Oat Cereal that its health 
claims regarding Cheerios® reducing cholesterol made Cheerios® an unapproved new 
drug). 
 25.  See § 321(p)(1) (requiring a product to first be a drug as defined by the FDCA, 
before considering whether the FDA has approved the product). 
 26.  See id. 
 27.  See § 355(a) (“No person shall introduce or deliver for introduction into 
interstate commerce any new drug, unless an approval of an application filed. . .”). 
 28.  See Weinberger v. Hynson, 412 U.S. 609, 629 (1973). 
 29.  See id. (holding “the hurdle of ‘general recognition’ of effectiveness requires 
at least ‘substantial evidence’ of effectiveness for approval of an NDA.”). 
 30.  See New Drug Application, FDA, http://www.fda.gov/drugs/develo
pmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/newdr
ugapplicationnda/default.htm (last visited Nov. 9, 2014) (stating that every new drug 
since 1938 has been subject to an approved NDA before United States 
commercialization). 
5
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Investigational New Drug Application (IND), which primarily focuses on 
development of the drug’s pharmacological profile and determination of its 
toxicity.
31
  The IND must demonstrate that the drug product is safe for 
testing in humans and that the clinical protocol is properly designed for its 
intended objectives.
32
  The IND requires a description of the proposed 
clinical studies (to assure studies would be acceptable for NDA 
consideration); product chemistry, manufacturing, and controls data 
(CMC); as well as summaries of the toxicological effects and biological 
disposition of the drug in animals and, if known, in humans (including non-
clinical data and data from foreign studies).
33
 
After the FDA is satisfied with the sponsor’s IND, the sponsor will begin 
Phase I clinical studies.
34
  Phase I typically involves using a small 
volunteer group to determine metabolic and pharmacological actions 
associated with increasing doses allowing for preliminary evidence of the 
drug’s effects.35  Once Phase I is concluded, Phase II begins with clinical 
studies composed of larger subject groups, which now include subjects 
with the condition that the drug is proposed to treat.
36
  The sponsor begins 
to collect preliminary data on effectiveness of the drug by looking at 
biological evidence that the drug is doing what it is supposed to do, while 
still examining the safety of the drug.
37
  If the drug is still producing 
evidence of effectiveness, and the adverse effects are tolerable, FDA allows 
the sponsor to move on to Phase III clinical studies.
38
  Phase III studies are 
                                                          
 31.  See 21 C.F.R. § 312.21. 
 32.  See id. § 312.22 (stating the general principles of IND); IND Application 
Reporting: Protocol Amendments, FDA, http://www.
fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/A
pprovalApplications/InvestigationalNewDrugINDApplication/ucm362503.htm (last 
visited Dec. 5, 2014) (allowing sponsor to progress from Phase I to Phase II to Phase 
III by submitting “protocol amendments” instead of a new IND for each phase). 
 33.  See § 312.23 (describing the contents required in IND); GUIDANCE FOR 
INDUSTRY BOTANICAL DRUG PRODUCTS 7, 18, FDA (June 2004) [hereinafter 
BOTANICAL GUIDANCE] available at http://www.fda.
gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm07049
1.pdf.   
 34.  See § 312.2 (requiring approval of IND application before clinical testing can 
begin).  
 35.  See The FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective, 
FDA, http://www.fda.gov/drugs/resourcesforyou/consumers/ucm143534.htm (last 
visited on Oct. 18, 2014) [hereinafter Drug Review Process] (providing that Phase I 
testing groups are generally 20 to 80 subjects). 
 36.  See id. (explaining Phase II groups have 100 to 300 subjects). 
 37.  See id.  
 38.  See id. (stating that effectiveness must be shown in Phase II trials before a drug 
sponsor may move on to Phase III trials). 
6
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typically expensive multi-year studies involving thousands of subjects with 
the sponsor studying different doses and population groups.
39
  After many 
years of research and, often the expenditure of more than a billion dollars, 
the sponsor can submit an NDA to the FDA to determine whether the drug 
will be marketable.
40
 
NDA regulations require the sponsor to provide the FDA with in-depth 
information regarding the drug, which includes the drug’s components, 
dosages, proposed labeling, and full reports of investigations into whether 
the drug is safe and effective.
41
  The FDA will withhold approval of a new 
drug unless the sponsor provides substantial evidence that the drug will 
have the effect it purports to have under conditions of use prescribed, 
recommended, or suggested on the labeling.
42
  An NDA must contain 
substantial evidence of effectiveness derived from adequate and well-
controlled clinical studies, evidence of safety, and adequate information of 
the product’s CMC, all submitted in the format that the FDA requires.43  
The FDA will approve the drug for sale if, after evaluation, the FDA 
determines that the drug’s benefits outweigh its risks.44 
However, even after approval of an NDA, the FDA monitors adverse 
event reports involving the approved drug, which could result in the drug 
being removed from the market if an unforeseen risk arises.
45
  Additionally, 
drug approval may be contingent on the sponsor’s inclusion of a voluntary 
                                                          
 39.  See id. (explaining Phase III clinical studies generally range from a few 
hundred to 3,000 participants); see also Martin S. Lipsky & Lisa K. Sharp, From Idea 
to Market: The Drug Approval Process, MEDSCAPE (2001), 
http://www.medscape.com/viewarticle/405869_1 (estimating 10% of medication fail in 
Phase III trials).  
 40.  See Matthew Herper, The Truly Staggering Cost of Inventing New Drugs, 
FORBES (Feb. 10, 2012, 7:41 AM), http://www.forbes.com/sites
/matthewherper/2012/02/10/the-truly-staggering-cost-of-inventing-new-drugs/ (finding 
that the average cost of bringing a drug to market is $1.3 billion).  
 41.  See 21 U.S.C § 355(b) (providing a detailed list of the contents that the drug 
sponsor is responsible for providing within the NDA). 
 42.  See id. §355(d) (providing a detailed list of factors that can result in approval 
being withheld besides general safety and effectiveness data, including lack of patent 
information and manufacturing details). 
 43.  See id. § 355 (providing the less specific statutory requirements required by 
Congress); 21 C.F.R. part 314.50 (providing regulations promulgated by FDA 
concerning a NDA’s content and format requirements, which is much more specific 
than what was originally provided by FDCA). 
 44.  See How FDA Evaluates Regulated Products: Drugs, FDA, 
http://www.fda.gov/AboutFDA/Transparency/Basics/ucm269834.htm (last visited Oct. 
18, 2014).  
 45.  See id. (describing the MedWatch database used to catalog adverse events 
involving drugs). 
7
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or involuntary restriction, or on the contingency that the sponsor continues 
Phase IV clinical studies after approval for further data.
46
 
4. The FDCA Gives the FDA Authority to Regulate Tobacco Products 
The FDA’s regulatory authority is vast reaching beyond the regulation of 
drugs to include such products as tobacco.
47
  In 2009, Congress passed the 
Family Smoking Prevention and Tobacco Control Act (TCA) giving the 
FDA authority to regulate the manufacturing, marketing, and sale of 
tobacco products.
48
  Congress enacted TCA with the understanding that 
tobacco is a legal product that poses some health risks and is only for 
adults.
49
  However, the FDA does not regulate tobacco like drugs under the 
strict safe and effective standard, but instead regulates tobacco under the 
new standard of “appropriate for the protection of the public health.”50 
The TCA creates multiple restrictions on the sale of tobacco: the 
purchaser must be at least eighteen years of age, purchases of tobacco 
products must be made face-to-face, and purchases are limited by 
quantity.
51
  Tobacco advertisements have extensive regulations, which 
attempt to eliminate any advertisements directed toward those under 
eighteen years of age.
52
  Additionally, tobacco products are misbranded if 
packaging makes unapproved “reduced harm” claims or the warning labels 
do not follow the specific visibility requirements.
53
  Regulations require 
                                                          
 46.  See Food and Drug Administration Amendments of 2007, Pub. L. No. 110–
85,121 Stat 922 (authorizing Risk Evaluation and Mitigation Strategies (REMS) post 
NDA approval, which provides that the FDA may require the drug sponsor to take 
additional actions regarding the labeling or dispensing of its drug in order to minimize 
potential risks). 
 47.  See generally 21 U.S.C. § 387 (2012) (providing the statutory framework for 
FDA’s regulation over tobacco).  
 48.  See generally Family Smoking Prevention and Tobacco Control and Federal 
Retirement Reform, Pub. L. No. 111-31, 123 Stat 1776. 
 49.  See Overview of the Family Smoking Prevention and Tobacco Control Act, 
FDA [hereinafter TCA Overview], http://www.fda.go
v/downloads/TobaccoProducts/GuidanceComplianceRegulatoryInformation/UCM3369
40.pdf (last visited Oct. 19, 2014) (recognizing a goal of tobacco regulation is to 
prevent those under eighteen from using an addictive and potentially harmful substance 
before fully understanding the consequences). 
 50.  See § 387f (authorizing Secretary to promulgate rules appropriate for the 
protection of the public health).  
 51.  See TCA Overview, supra note 49. 
 52.  See, e.g., id. (banning tobacco advertisements within 1,000 feet of a school or 
playground, as well as banning tobacco advertisement from sporting and entertainment 
events).  
 53.  See § 387c (providing that any tobacco product that does not comply with all 
labeling regulations may be misbranded); § 387k (restricting the use of “reduced risk” 
8
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tobacco manufactures to register with the FDA and be subject to 
inspections.
54
  Further, the tobacco industry must disclose all research on 
health, toxicological, behavioral, or physiologic effects of tobacco use.
55
  
The FDA may implement standards for tobacco products to regulate such 
things as nicotine levels, pesticide use, and manufactures discloser of all 
tobacco product components.
56
  Additionally, if the product contains an 
extraneous component that is harmful it is adulterated, and the FDA may 
seize it.
57
  Pre-market review may also be required for new tobacco 
products if they present a significant variation from currently marketed 
tobacco products.
58
 Manufacturers of all new tobacco products must file a 
substantial equivalence report with the FDA, and the new tobacco products 
can be legally marketed without premarket review only if the FDA 
determines the new products are substantially equivalent to a predicate 
tobacco product.
59
 
However, while the TCA provides the FDA with significant regulatory 
power over tobacco, there are still restraints on the FDA’s authority over 
tobacco.
60
  The FDA cannot ban certain classes of tobacco products, 
require zero nicotine, require prescriptions to purchase tobacco, establish a 
minimum age older than 18 years old, or ban face-to-face sales in any 
particular category of retail outlets.
61
 
                                                          
terms on labeling, such as light, low, or mild); § 387h (extending FDA recall authority 
to misbranded or adulterated products).  
 54.  See § 387e (listing specific annual registration requirements for tobacco 
manufacturers, including facilities and products). 
 55.  See § 387d (b) (requiring data submissions relating to research activities of 
tobacco manufacturer); § 387e (listing specific annual registration requirements for 
tobacco manufacturers, including facilities and products); § 387i (requiring 
manufacturers to keep specified records, which Secretary may request). 
 56.  See § 387d (a)(1) (requiring disclosure of tobacco product compounds); § 387g 
(banning the use of artificial or natural flavors as a component of cigarettes; requiring 
tobacco producer to abide by set pesticide levels). 
 57.  See § 387b (defining adulterated tobacco products as those that are filthy, 
poisonous, and/or deleterious); § 387h (extending FDA recall authority to adulterated 
products). 
 58.  See § 387j (requiring an application attesting that the new tobacco product has 
the same characteristics as a predicate tobacco product, or provide clinical data to 
support differing characteristics pose no threat to public health).  
 59.  See id. (defining “predicate tobacco product” as a tobacco product that was 
commercially marketed (other than in a test market) as of February 15, 2007, or a 
product previously found to be substantially equivalent by the FDA and in compliance 
with the requirements of the FDCA).  
 60.  See generally §§ 387f (d), 387g (d). 
 61.  See §§ 387f (d), 387g (d) (providing safeguards to insure at least a minimum 
level of access to standard tobacco products).  
9
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Tobacco presents addictive and dangerous qualities, which, surprisingly, 
has only brought it under the FDA’s regulation relatively recently.62  
Tobacco has a long history in the United States: economic forces coupled 
with consumer needs provided the tobacco industry with political influence 
and the ability to silence the anti-tobacco movements.
63
  Scientific findings 
and political leadership led to the tobacco industry’s objection to regulation 
and liability.
64
 
III. ANALYSIS 
A. Marijuana Could Not Be Regulated as a Drug Because the FDA 
Would Not Approve an NDA Proposing Marijuana Be Used for a Medical 
Purpose 
As a botanical product, marijuana faces a variety of challenges regarding 
standardization and CMC data that regular synthetic or highly purified 
drugs do not encounter because they are created in a lab versus grown from 
the ground.
65
  Currently, only two botanical drug products have met the 
strict NDA requirements and received FDA approval.
66
 
 
1. Marijuana Fits Firmly into the FDCA’s Definition of a Drug, Which 
Would Require Marijuana Be  Regulated Under the “Drug” Statutes 
Without a federal statute expressly defining marijuana as something 
other than a drug, marijuana squarely fits within the FDCA’s definition of a 
drug.
67
  FDCA defines “drug” as any article listed in a major 
                                                          
 62.  See TCA Overview, supra note 49 (discussing 2009 amendment allowing FDA 
regulation of tobacco products).  
 63.  See Paul Verkuil, “A Leadership Case Study of Tobacco and its Regulation”, 
PUBLIC TALK, http://www.upenn.edu/pnc/ptverkuil.html (last visited Nov. 15, 2014) 
(explaining first anti-tobacco movements began in 1604, but were overcame by profit 
motives). 
 64.  See id. (discussing the Clinton Administrations involvement in warning the 
public of tobacco’s health risks, which helped decrease tobacco industry’s political 
power).  
 65.  See BOTANICAL GUIDANCE, supra note 33, at 2, 5 (defining “botanical 
product” for purposes of FDA guidance and discussing possible issues within drug 
approval process).  
 66.  FDA approves first anti-diarrheal drug for HIV/AIDS patients, FDA, 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333701.htm 
(last visited Oct. 19, 2014) (stating that the FDA has only approved two botanical 
drugs, Fulyzaq in 2012 and Veregen in 2006). 
 67.  See generally 21 U.S.C. §§ 351-361 (2012) (creating the regulatory framework 
for drugs and devices). 
10
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pharmaceutical compendium, intended to treat, mitigate, or diagnose a 
medical condition; or is intended to affect the structure or function of its 
consumer.
68
  The United States Pharmacopeia (USP) and the National 
Formulary (NF) both listed marijuana in their publications from 1850 until 
1942, at which time marijuana was prescribed for various conditions 
including labor pains, nausea, and rheumatism.
69
  Today, the use of medical 
marijuana is recognized in multiple states, allowing the medicinal use of 
marijuana for treating Alzheimer’s disease, anorexia, AIDS, arthritis, 
cachexia, cancer, Crohn’s disease, epilepsy, glaucoma, HIV, migraines, 
multiple sclerosis, nausea, pain, spasticity, and wasting syndrome.
70
  
Additionally, marijuana is commonly smoked by users for its stimulating 
effect on the brain causing the release of dopamine, which produces a 
euphoric sensation, or “high.”71  Marijuana’s prescribed use for treating 
diseases and conditions, and its effect on the brain’s function clearly make 
marijuana a “drug” as defined by the FDCA.72 
2. Marijuana Is a “New Drug” Because It Lacks an Approved NDA 
Marijuana’s inclusion in the broadly defined drug category does not 
automatically require preapproval before marketing; however, it does make 
marijuana subject to a “new drug” analysis, which requires premarket 
approval if the article is a new drug.
73
  Not only is marijuana a “drug,” but 
it is also a “new drug.”74  Marijuana is a new drug because it is not 
                                                          
 68.  See § 321(g)(1); Lewis A. Grossman, Food, Drugs, and Droods: A Historical 
Consideration of Definitions and Categories in American Food and Drug Law, 93 
CORNELL L. REV. 1091, 1127 (July 2008) (stating that, despite the language of the 
FDCA, the FDA and the courts do not regard inclusion of a substance in the compendia 
as in and of itself sufficient for drug classification). 
 69.  See Gerald Gianutsos, Medical Marijuana: Therapeutic Uses and Legal Status, 
US PHARMACIST (Oct. 1, 2010), http://www.uspharmacist.com
/continuing_education/ceviewtest/lessonid/106975/ (stating marijuana has been 
cultivated in the United States since 1611). 
 70.  See UNITED STATES GENERAL ACCOUNTING OFFICE, MARIJUANA EARLY 
EXPERIENCES WITH FOUR STATES’ LAWS THAT ALLOW USE FOR MEDICAL PURPOSES, 
51-53 (2002), available at http://www.gao.gov/assets/240/236305.pdf.  
 71.  See How does marijuana produce its effects?, NAT’L INST. ON DRUG ABUSE, 
http://www.drugabuse.gov/publications/research-reports/marijuana/how-does-
marijuana-produce-its-effects (last viewed May 12, 2014). 
 72.  See id. (discussing marijuana’s effects on brains regulation of balance, posture, 
coordination, and reaction time). 
 73.  See 21 C.F.R. § 310.100 (2014) (explaining that some drugs marketed before 
1938 are covered under a grandfather clause allowing those drugs to be marketed 
without premarket approval as long as drug has not changed in formulation, 
manufacture control, or labeling in a way that may significantly affect safety of drug). 
 74.  See generally 21 U.S.C. § 355 (2012) (proving the statutory regulations for 
11
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generally recognized by scientific experts as safe and effective for use 
under the conditions prescribed or recommended.
75
  Without having been 
deemed safe and effective, “new drugs” are prohibited from being 
introduced into commerce.
76
  While marijuana has been in society and used 
medicinally for a long time, the FDA states that a drug is a “new drug” if 
marketed without an FDA approved New Drug Application (NDA), and 
marijuana has no uses that have been approved through the NDA process.
77
  
Currently, the FDA’s position on the medicinal use of marijuana is clear; it 
explicitly concluded in 2011 that marijuana has a high potential for abuse, 
is not currently recognized for medical use, and is unsafe to use under 
medical supervision.
78
  Marijuana has not been subjected to the NDA 
process, nor has it been generally recognized as safe and effective for 
treating and conditions, so it is a “new drug” under the FDCA that would 
be illegal to sell.
79
 
3. Marijuana Would Likely Not Be Approved in the NDA Process 
Because as a Botanical Drug It Is Difficult to Standardize Marijuana to 
Ensure Consistent Dosing and Active Constituents 
For marijuana to become recognized as safe and effective for a particular 
use, FDA would have to approve a New Drug Application (NDA) 
proposing marijuana be used to treat a specific condition or disease.
80
  An 
NDA requires the sponsor to provide the FDA with in-depth information 
regarding the drug, including the drug’s components, dosages, proposed 
labeling, and full reports of investigations into whether the drug is safe and 
effective.
81
  The FDA will withhold approval of a new drug unless the 
sponsor provides substantial evidence that the drug will have the effect it 
purports to have under conditions of use prescribed, recommended, or 
                                                          
new drugs).  
 75.  See id. § 321(p)(1) (defining “new drug”). 
 76.  See id. § 355(a) (“No person shall introduce or deliver for introduction into 
interstate commerce any new drug,” unless the new drug’s NDA has been approved). 
 77.  See FDA and Marijuana, FDA, 
http://www.fda.gov/NewsEvents/PublicHealthFocus/ucm421163.htm (last visited May 
8, 2015) [hereinafter FDA and Marijuana] (stating that “FDA has not approved 
marijuana as a safe and effective drug for any indication.”). 
 78.  See 76 Fed. Reg. 40552 (July 8, 2011) (denying petition to reschedule 
marijuana). 
 79.  See § 321(p)(1) (stating that a drug is a new drug is not generally recognized as 
safe and effective among experts); FDA and Marijuana, supra note 96 (stating that 
marijuana has not been generally recognized as safe and effective among experts). 
 80.  See § 355(b) (requiring an NDA to provide reports of the drugs effective use). 
 81.  See id.  
12
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suggested on the labeling.
82
  As discussed above, substantial evidence of 
effectiveness and safety ordinarily must be proven by three stages of well-
controlled clinical studies.
83
 
a. IND Approval for Phase I and Phase II Studies 
Before marijuana could be tested in clinical studies, the sponsor would 
have to submit an IND providing an overview of marijuana’s chemical 
constituents, manufacturing and processing, safety data, and details on the 
proposed clinical studies.
84
  Providing marijuana’s chemical constituents 
would be the first difficulty when submitting an IND because scientists 
continue to have difficulty identifying some of the hundreds of chemical 
constituents in.
85
  In a guidance document, however, the FDA has 
recognized that in many cases the active constituent in a botanical drug is 
not identified, nor is its biological activity well characterized, and thus has 
suggested that active constituents need not be completely identified during 
the IND process.
86
 
Nevertheless, the FDA would evaluate other factors of the IND more 
critically because of the lack of knowledge concerning marijuana’s active 
constituents.
87
  The FDA’s general guidance on botanicals, as applied to 
marijuana, suggest a combination of tests and controls would need to be 
implemented in order to ensure the identity, purity, quality, strength, 
potency, and consistency of marijuana.
88
  The manufacturing process will 
need to be well-defined within the CMC portion of the IND including 
                                                          
 82.  See § 355(d)-(e) (stating NDA approval will be withdrawn upon finding 
imminent hazard to public health). 
 83.  See Drug Review Process, supra note 35 (overviewing FDA’s drug review 
process: animal testing, IND, Phase I–III testing, review meeting, NDA submission, 
NDA review). 
 84.  See id.; 21 C.F.R. § 312.22 (2014) (stating that IND must contain sufficient 
information to demonstrate that drug product is safe for testing in humans and that 
clinical protocol is properly designed for its intended objectives).  
 85.  What Chemicals Are in Marijuana and Its Byproducts?, PROCON, 
http://medicalmarijuana.procon.org/view.answers.php?questionID=636 (last updated 
Aug. 8, 2009, 6:11 PM) (discussing composition of marijuana and difficulties with 
determining all of its compounds).  
 86.  See BOTANICAL GUIDANCE, supra note 33, at 5 (suggesting that constituents do 
not need to be fully identified during IND, but will need to be further identified for 
ultimate NDA approval). 
 87.  See id. (suggesting more stringent manufacturing controls to insure consistent 
product is constituents cannot be identified). 
 88.  See id. (including (1) multiple tests for drug substance and drug product, (2) 
raw material and process controls, and (3) process validation).  
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adequate in-process controls.
89
 
Consistency could be the biggest challenge because variations in soil, 
geographical region, water, light, harvesting, and storage condition 
magnify the inconstant chemical makeup of marijuana and make marijuana 
standardization nearly impossible.
90
  If the drug sponsor cannot show the 
ability to consistently produce a single formulation and dose of marijuana 
from batch-to-batch the FDA would likely deny the NDA because 
inconsistencies between batches would cause uninterpretable results in the 
clinical trial.
91
 IND approval only permits the drug sponsor to conduct 
clinical trials with the new drug, which will provide the data that is 
ultimately submitted for NDA consideration.
92
  If the clinical trials do not 
conform to clinical standards the FDA will likely deny the drug sponsors 
NDA because the results of the studies are not credible.
93
  The dosage and 
composition of the marijuana will be very important during clinical trials to 
ensure credible results for the NDA.
94
  However, marijuana plants do not 
need to be produced perfectly identical.
95
  “Different plant strains and 
batches vary radically in their levels of psychoactive substances and in the 
contaminants — fungi, bacteria, pesticides, heavy metals and other 
substances — they contain.”96  The drug sponsor must state in the IND how 
it would control all of these factors in order to produce a standardized 
product.
97
  Although lack of standardization would not prevent approval of 
the IND for initial clinical trials, it could hinder IND proposals for Phase 
                                                          
 89.  See § 312.23(a)(7)(iv). 
 90.  See Claire Frezza, Medical Marijuana: A Drug Without A Medical Model, 101 
Geo. L.J. 1117, 1135 (2013) (quoting Suzanne D. McGuire, Comment, Medical 
Marijuana: State Law Undermines Federal Marijuana Policy—Is the Establishment 
Going to Pot?, 7 SAN JOAQUIN AGRIC. L. REV. 73, 74-75 (1997)). 
 91.  See BOTANICAL GUIDANCE, supra note 33, at 11-12 (recommending the 
sponsor outline its ability to produce batch-to-batch consistency within the CMC data). 
 92.  See Drug Review Process, supra note 35. 
 93.  See generally § 314.125 (stating reasons for NDA refusal, including, 
inadequate methods for controls). 
 94.  See BOTANICAL GUIDANCE, supra note 33, at 11-12 (recommending a single 
formulation and a single dosage form be used throughout different states of the clinical 
trials unless impossible). 
 95.  See id. (suggesting samples be retained from Phase I and Phase II trials for 
product comparison with the product used in Phase III trials to ensure batch 
consistency). 
 96.  See Henry I. Miller, The Real Dope On Medical Marijuana, FORBES (Mar. 28, 
2012, 10:56 AM), http://www.forbes.com/sites/henrymiller/2012/03/28/the-real-dope-
on-medical-marijuana/.  
 97.  See BOTANICAL GUIDANCE, supra note 33, at 10-12 (discussing CMC 
requirements of § 312.23(a)(7)).  
14
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III clinical studies and, ultimately, the approval of its NDA.
98
 
Showing that marijuana can be standardized through testing and controls 
is important for IND approval, but a showing that marijuana is safe for 
human studies is more important.
99
  The drug sponsor must provide 
pharmacological and toxicological information within the IND.
100
  The 
proposed dose of marijuana to be tested must be shown to be safe through 
clinical and nonclinical data, which may include studies not conducted by 
the sponsor (e.g. foreign studies).
101
  The sufficiency of data required for 
Phase I and Phase II testing is relatively low compared to what is necessary 
for Phase III testing.
102
 
Moreover, the extensive use of marijuana in humans already may 
provide sufficient information to support initial clinical studies, forgoing 
the standard in vivo or in vitro experiments testing articles under laboratory 
conditions which the FDA generally requires.
103
  Currently, there are a 
variety of peer-reviewed studies weighing in on the safety and efficacy of 
marijuana that provide data for the FDA’s consideration.104  Arguably, the 
largest safety concern of marijuana is the delivery method: smoking 
presents issues of pulmonary disease and lung cancer.
105
  The safety of 
                                                          
 98.  See 21 U.S.C. §355(d) (2012) (requiring NDA to contain substantial evidence 
of effectiveness derived from adequate and well-controlled clinical studies); 
BOTANICAL GUIDANCE, supra note 33, at 11-12 (explaining the importance of product 
consistency for Phase III trials). 
 99.  See 21 C.F.R. §312.22 (2014) (requiring IND to contain sufficient information 
to demonstrate that drug product is safe for testing in humans). 
 100.  See id. § 312.23(a)(8) (describing content and format of pharmacological and 
toxicological information to be provided in IND).  
 101.  See BOTANICAL GUIDANCE, supra note 33, at 13 (stating less safety data is 
necessary for initial clinical trials then what is expected from by synthetic or highly 
purified drugs).  
 102.  See id.; Drug Review Process, supra note 35 (explaining that Phase I testing is 
used to determine safety and side effects on healthy individuals).  
 103.  See BOTANICAL GUIDANCE, supra note 33, at 25-26 (comparing herbal 
products with extensive human use that require less safety testing to synthetic drugs 
with little to no human use that require more extensive nonclinical safety testing).  
 104.  See 60 Peer-Reviewed Studies on Marijuana, PROCON, 
http://medicalmarijuana.procon.org/view.resource.php?resourceID=000884 (last 
updated Feb. 27, 2015) (providing medical studies involving cannabis and cannabis 
extracts, from 1990-2014).  
 105.  See Jenny Hope, Cannabis ‘kills 30,000 a year’, DAILY MAIL, 
http://www.dailymail.co.uk/health/article-179264/Cannabis-kills-30-000-year.html 
(last visited Oct. 24, 2014) (speculating that marijuana smokers suffer from lung 
disease at same rates as cigarette smokers); MARIJUANA AND MEDICINE ASSESSING THE 
SCIENCE BASE 6, IOM (1999), available at http://medicalmarijuana.procon.org
/sourcefiles/IOM_Report.pdf (recommending marijuana not be smoked because of 
15
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marijuana is widely debated; however, due to the low threshold of safety 
data required for initial studies, marijuana would be safe enough to 
progress to clinical studies.
106
  Upon IND approval for Phase I and Phase II 
studies, the drug sponsor would further identify marijuana’s constituents, 
continue to develop safety data, and begin to establish an effective dose of 
marijuana.
107
 
b. IND Approval for Phase III Studies 
IND approval for Phase III studies of marijuana will be much more 
difficult to obtain because the sponsor is expected to provide more detailed 
information of CMC and safety than when conducting a Phase I or Phase II 
study.
108
  The FDA would require additional safety data in order to support 
marijuana’s use among a much larger subject population size.109  As in 
Phase I and Phase II, past human and animal studies will be considered; 
however, further systematic toxicological evaluations could be needed to 
supplement available knowledge on the general toxicity, teratogenicity, 
mutagenicity, and carcinogenicity of the final marijuana product.
110
 
Further detail regarding CMC data is required to ensure the 
reproducibility of the substance.
111
  If the marijuana cannot be standardized 
through manufacturing and controls, the Phase III trials are unlikely to 
produce consistent data supporting the use of marijuana for the chosen 
                                                          
harmful effects of smoking).  
 106.  See Deaths from Marijuana v. 17 FDA-Approved Drugs, PROCON, 
http://medicalmarijuana.procon.org/view.resource.php?resourceID=000145 (last visited 
Oct. 24, 2014) (demonstrating that there are fewer marijuana related deaths than 
compared to many FDA approved drugs). But see Roxanne Khamsi, How Safe Is 
Recreational Marijuana?, SCIENTIFIC AMERICAN (May 14, 2013), http://www.scientific
american.com/article/how-safe-recreational-marijuana/?page=2 (describing marijuana’s 
negative effects to cognitive and motor function).  
 107.  Drug Review Process, supra note 35 (stating Phase I testing focuses on safety, 
and Phase II testing examines effectiveness). 
 108.  See 21 C.F.R. § 312.22(b) (2014) (stating that information required for IND 
approval is based on which Phase is being approved); BOTANICAL GUIDANCE, supra 
note 33, at 27 (presenting guidance that more detailed information is required for Phase 
III studies).  
 109.  See BOTANICAL GUIDANCE, supra note 33, at 27 (requiring additional 
toxicology data to support the product’s wider use within Phase III); Drug Review 
Process, supra note 35 (explaining that in Phase III trials the subject group is generally 
between several hundred and 3,000 people).  
 110.  See BOTANICAL GUIDANCE, supra note 33, at 34-35 (depending on indication, 
rout of administration and duration of recommended drug exposure, and other 
requirements, nonclinical animal studies can vary).  
 111.  See BOTANICAL GUIDANCE, supra note 33, at 27 (stressing the importance of 
reproducibility in ensuring consistent data in well-controlled trials).  
16
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condition.
112
  Standardizing marijuana requires producing batches of plants 
with qualitatively and quantitatively comparable chemical constituents.  
Batch to batch inconsistency will likely plague marijuana’s approval 
because many strains of marijuana exist, each presenting a different variety 
of characteristics.
113
  Additionally, environmental factors would create 
further inconsistencies within each batch of marijuana.
114
  One could 
imagine that Phase III studies would produce inconsistent data if a main 
active constituent, say Tetrahydrocannabinol (THC), was found at different 
levels per unit of marijuana.
115
  However, the solution to producing 
consistent batches of marijuana could be the implementation of extensive 
manufacturing controls.
116
  The sponsor achieves quality and consistency of 
the final drug product by controlling the botanical source and adequate 
blending, in combination with other downstream CMC controls on the 
manufacturing processes.
117
  The final studies towards proving marijuana’s 
effectiveness would commence upon the approval of marijuana’s IND for 
Phase III.
118
 
                                                          
 112.  See id.  
 113.  See Cannabis Strain and Infused Product Explorer, LEAFLY, 
http://www.leafly.com/explore (last visited Oct. 30, 2014) (documenting 1024 strains 
of marijuana and general characteristics of each strain); cf. CENTER FOR DRUG 
EVALUATION AND RESEARCH, CROSS DISCIPLINE TEAM LEADER REVIEW APPLICATION 
NUMBER 202292ORIG1S000 7-12, (2012), available at http://www.accessdata.fda
.gov/drugsatfda_docs/nda/2012/202292Orig1s000CrossR.pdf (noting CMC issues 
Fulyzaq, the second botanical drug ever approved, faced during NDA review). 
 114.  See Frezza, supra note 90, at 1135 (quoting Suzanne D. McGuire, Comment, 
Medical Marijuana: State Law Undermines Federal Marijuana Policy—Is the 
Establishment Going to Pot?, 7 SAN JOAQUIN AGRIC. L. REV. 73, 74-75 (1997)). 
 115.  See Karl W. Hillig & Paul G. Mahlberg, A CHEMOTAXONOMIC ANALYSIS OF 
CANNABINOID VARIATION IN CANNABIS (CANNABACEAE), 91 AM. J. BOT. 966, 971-73 
(June 2004), available at http://www.amjbot.org/content/91/6/966.full.pdf+html 
(finding that various environmental and genetic factors determine the qualitative and 
quantitative levels of cannabinoids within marijuana).  
 116.  See BOTANICAL GUIDANCE, supra note 33, at 5 (suggesting the use of 
manufacturing controls to ensure identity, purity, quality, strength, potency, and 
consistency of botanical drugs).  
 117.  Cf. BOTANICAL REVIEW APPLICATION NUMBER 21-202, CENTER FOR DRUG 
EVALUATION AND RESEARCH (Oct. 31, 2006), available at http://www.acc
essdata.fda.gov/drugsatfda_docs/nda/2006/021902s000_botanicalr.pdf (noting 
recommendations for standardizing Veregen, the first botanical drug approved by the 
FDA, during NDA review).   
 118.  See Drug Review Process, supra note 35 (noting Phase III studies further test 
safety and effectiveness among different patient populations and dosages).  
17
Erly: High Times: Is The Federal Legalization of Marijuana Next?
Published by Digital Commons @ American University Washington College of Law, 2015
 676 JOURNAL OF GENDER, SOCIAL POLICY & THE LAW  [Vol. 23:4 
c. NDA Review 
While the duration of clinical studies vary, the process of clinical testing 
and NDA review for marijuana may take upwards of fifteen years to 
complete.
119
  It will be up to marijuana’s sponsor to successfully show that 
marijuana is safe and effective for treating a specific condition or 
disease.
120
  There is no specific number or value that all drugs are 
compared to when determining safety and effectiveness.
121
 Instead, the 
FDA applies a risk-benefit analysis.
122
  Marijuana does not need to be more 
effective than existing treatments for approval;
 
marijuana only needs to be 
proven effective through clinical testing.
123
  The FDCA does not clearly 
define “safe,” and thus the FDA would base its determination on whether 
the benefits of marijuana outweigh the potential risks.
124
  The technical 
requirements are equally important, such as demonstrating that the 
manufacturer can produce a standardized marijuana product and that the 
clinical trials supporting marijuana’s effectiveness were conducted in 
accordance to good clinical practice (GCP).
125
  If marijuana’s NDA is 
                                                          
 119.  How long does it take for a new drug to go through clinical trials?, CANCER 
RESEARCH UK, http://www.cancerresearchuk.org/about-cancer/cancers-in-
general/cancer-questions/how-long-does-it-take-for-a-new-drug-to-go-through-clinical-
trials (last visited Nov. 2, 2014) (explaining time it take to complete clinical trials 
varies on type of disease, method of treatment, number of patients needed, length of 
treatment, length of follow up period required, and any problems encountered).  
 120.  21 U.S.C. § 355(b)(1) (2012) (requiring NDA to be filed demonstrating a new 
drug’s safety and effectiveness).  
 121.  Brady Dennis, FDA’s ‘safe and effective’ drug approvals based on widely 
varied data, study finds, WASH. POST (Jan. 21, 2014), 
http://www.washingtonpost.com/national/health-science/fda-drug-approvals-based-on-
varied-data-study-finds/2014/01/21/b12d0712-82be-11e3-8099-
9181471f7aaf_story.html (discussing that FDA’s determination of safe and 
effectiveness lacks uniformity, and that amount of data required for one drug’s 
approval may not suffice for another’s). 
 122.  See id.  
 123.  See 21 C.F.R. § 314.105 (2014) (stating that the FDA has flexibility in 
applying statutory standards, and uses its own scientific judgment to determine the kind 
and quantity of data and information an applicant is required to provide for a particular 
drug to meet the statutory standards); Robert J. Temple, Comparative Effectiveness 
Research, FDA (Apr. 21, 2010), http://www.fda.gov/downloads/Drugs/NewsEvents
/UCM209270.pdf (stating that legislative history is clear, a new drug does not have to 
be better than, or as good as existing treatments). 
 124.  Structured Approach to Benefit-Risk Assessment in Drug Regulatory 
Decision-Making, FDA (Feb. 2014), available at http:/
/www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM32975
8.pdf (recognizing that all drugs have the ability to cause adverse effects, and thus are 
examined on a benefit-risk assessment unique to each case).  
 125.  See BOTANICAL GUIDANCE, supra note 33, at 33 (recommending that batch-to-
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submitted with careful consideration to FDA guidance and regulations then 
the FDA’s decision should follow within ten months.126  Assuming 
marijuana’s sponsor is able to show the necessary effectiveness and safety, 
the CMC issues would still have to be worked out in order to assure 
consistency of the product and, ultimately, approval from the FDA.
127
  
Additionally, if marijuana were approved, only the specific strain of 
marijuana that received an approved NDA would be available by 
prescription.
128
  Any changes to the approved marijuana product would 
require additional FDA premarket approval.
129
 
B. Marijuana Regulated Under the Tobacco Provisions of the FDCA 
Much like drugs, tobacco is regulated to minimize its harmful effects to 
society; however, tobacco regulation is much less restrictive and provides 
greater accessibility.
130
  Marijuana should be regulated like tobacco by 
recognizing marijuana as a legal product that is only for adults, even 
                                                          
batch consistency be shown); Clinical Trial Guidance Documents, FDA, 
http://www.fda.gov/RegulatoryInformation/Guidances/ucm122046.htm (last visited 
Nov. 2, 2014) (providing documents on what the FDA considers to be good clinical 
practice because how clinical trials are conducted is taken into consideration during 
NDA review). 
 126.  See Dhiren N. Shah, OBTAINING APPROVAL OF NEW DRUG APPLICATIONS AND 
ABBREVIATED NEW DRUG APPLICATIONS FROM A CHEMISTRY, MANUFACTURING, AND 
CONTROLS PERSPECTIVE 406, AVENTIS PHARMACEUTICALS (2005), available at http://
www.slideshare.net/priyankagangarapu/nda-anda-approval (noting from a technical 
regulatory perspective, if all the work is done properly as described in sections a-h, the 
NDA submission should become fairly easy); Drug Review Process, supra note 35 
(stating that 90% of NDA applications are acted upon within 10 months).  
 127.  See 21 U.S.C. § 355(d) (2013) (stating that a NDA may be refused if the 
methods used, and the facilities and controls used for, the manufacture, processing, and 
packing of such drug are inadequate to preserve its identity, strength, quality, and 
purity). 
 128.  See § 353(b) (requiring drugs that present potential safety issues be only 
prescribed by a licensed practitioner, and only be dispensed by a pharmacist).  
 129.  See GUIDANCE FOR INDUSTRY CHANGES TO AN APPROVED NDA OR ANDA, 
FDA (Apr. 2004), available at http://www.fda.gov/downloads/drugs/
guidancecomplianceregulatoryinformation/guidances/ucm077097.pdf (explaining 
changes to an approved drug that effect its identity, strength, quality, purity, or potency 
must be submitted to FDA for approval before further marketing). 
 130.  See, e.g., § 387f (d) (preventing the promulgation of rules that would require a 
prescription for tobacco). But see Drugs Applications for Over-the-Counter (OTC) 
Drugs, FDA, http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredeve
lopedandapproved/approvalapplications/over-the-counterdrugs/default.htm (last viewed 
Dec. 4, 2014) (explaining OTC drugs are safe and effective for use by general public 
without seeking treatment by a health professional).  
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though it poses potential health risks.
131
  The Secretary of HHS would also 
possess the authority to promulgate rules, upon Congress specifically 
giving the FDA authority over marijuana, appropriate to minimizing the 
potential risks of marijuana, while still allowing society to access it with 
great ease as compared to drug regulations.
132
  The FDA would regulate 
almost every aspect of the marijuana industry, including manufacturing, 
labeling, advertising, and sale.
133
 
The manufacturing of marijuana could be regulated in multiple ways 
similar to how tobacco is regulated, which would ensure that consumers get 
the safest product possible.
134
  Manufactures would have to disclose all 
components of the marijuana products, and the FDA could regulate the 
amounts of each component, such as THC.
135
  Additionally, the FDA 
would have the authority to impose strict quality standards to assure 
nothing is introduced into the marijuana that could present additional risks 
to the consumer, such as intentional or unintentional chemical additives.
136
 
Restrictions on labeling and advertisement would allow the FDA to 
control the information consumers get about marijuana, as well as which 
consumers are targeted with that information.
137
  Like the FDA’s goal in 
regulating tobacco, the goal with marijuana will be ensuring people are 
aware of its risks, and preventing marijuana use among minors.
138
  Labeling 
                                                          
 131.  See TCA Overview, supra note 49 (explaining a goal of tobacco regulation is 
to prevent use of a potentially harmful substance before fully understanding risks). 
 132.  See § 387f (giving HHS Secretary authority to create rules promoting public 
health with regards to tobacco).  
 133.  See generally § 387 (imposing regulations upon tobacco sales, advertising, 
labeling, and manufacturing).  
 134.  See § 387d (b) (requiring data submissions relating to research activities of 
tobacco manufacturer); § 387e (listing specific annual registration requirements for 
manufacturers, including facilities and products); § 387i (requiring manufacturers to 
keep and present specified records on request); § 387t(2) (allowing promulgation of 
rules related to inspection). 
 135.  See § 387d (a)(1) (requiring disclosure of tobacco product compounds); § 387g 
(stating tobacco product standards); Drug Facts: Marijuana, NATIONAL INSTITUTE ON 
DRUG ABUSE (January 2014), 
http://www.drugabuse.gov/publications/drugfacts/marijuana (arguing increase of THC 
in marijuana creates adverse effects).  
 136.  See § 387b (defining tobacco products that are filthy, poisonous, or deleterious 
as adulterated); § 387h (explaining FDA’s recall authority of misbranded or adulterated 
products). 
 137.  See TCA Overview, supra note 49 (banning tobacco advertisements within 
1,000 feet of a school or playground, as well as banning tobacco advertisement from 
sporting and entertainment events). 
 138.  See id. (explaining a goal of tobacco regulation is to prevent use of a 
potentially harmful substance before fully understanding risks). 
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restrictions would effectively eliminate manufacturers from marketing their 
products as safe, and would impose visibility requirements on any health 
warnings the Secretary of HHS deems necessary.
139
  Marijuana 
manufacturers under such a regime could not market their products as safe 
because marijuana has side effects, including diminished cognitive 
performance and many of the same respiratory illnesses associated with 
smoking tobacco.
140
 
Furthermore, sales regulations on marijuana could reduce access to the 
substance for minors.
141
  The Secretary of HHS could impose an age 
restriction on sales of marijuana.
142
  An age restriction would mean that no 
business, in any state, could sell marijuana to an individual under a specific 
age.
143
  Equally important, the Secretary is restricted from making the 
minimum age greater than eighteen years old for tobacco, and thus still 
maintaining access for the adult population.
144
  By using the tobacco model 
as the framework for marijuana regulation, a minimum age should be 
imposed, but experts may want to impose a different age than that of 
tobacco because of marijuana’s effects on brain development.145 
The tobacco provisions that are most distinguishable from the drug 
model are those that limit the FDA’s authority to promulgate rules that 
would severely restrict access to tobacco, e.g., not allowing the FDA to 
restrict face-to-face sale, to ban certain categories of tobacco, or to require 
prescriptions to purchase tobacco.
146
  These limitations decrease the FDA’s 
                                                          
 139.  See § 387c (stating a tobacco product that does not have proper labeling or is 
misleading will be considered misbranded); § 387k (restricting use of “reduced risk” 
terms on labeling, such as light, low, or mild); § 387h (explaining that the FDA has 
authority to recall a product if it is misbranded). 
 140.  See Drug Facts: Marijuana, supra note 135 (finding marijuana smoke to be a 
lung irritant causing daily cough and phlegm production, more frequent acute chest 
illness, and a heightened risk of lung infections).  
 141.  See TCA Overview, supra note 49.  
 142.  Cf. § 387f(d) (allowing promulgation of restrictions on sale and distribution of 
a tobacco products). 
 143.  See id. (providing authority to promulgate rules appropriate for the protection 
of the public health). 
 144.  See § 387f (d)(3)(A)(ii) (limiting the Secretary’s ability to establish a 
minimum age older than 18 year old for tobacco products).  
 145.  See Drug Facts: Marijuana, supra note 135 (explaining that heavy marijuana 
during adolescent years causes a decline in IQ); Michael Martinez, 10 things to know 
about nation’s first recreational marijuana shops in Colorado, CNN (Jan. 1, 2014), 
http://www.cnn.com/2013/12/28/us/10-things-colorado-recreational-marijuana/ 
(requiring marijuana buyers to be 21 or older in Colorado). 
 146.  See generally § 387f (d)(3)(A) (detailing restrictions on the Secretaries rule 
making authority). 
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authority enough to ensure access to tobacco products, and thus would 
provide easier access to marijuana, especially compared to marijuana 
regulated under the drug provisions.
147
  If marijuana were regulated with 
these same access-promoting provisions as tobacco, it would remain 
regulated, but not to the point of being regulated out of the market as would 
happen if marijuana were regulated as a drug.
148
 
1. Premarket Approval for “New Tobacco Products” Could Not Be Used 
to Regulate New Marijuana Products Because the Analysis Is based on 
Previously Marketed Products 
FDCA provides that “new tobacco products” must be pre-approved by 
the FDA before being marketed.
149
  This provision would not work with 
marijuana because the premarket review compares the new tobacco product 
to tobacco products that are currently being commercially marketed.
150
  A 
provision comparing new products to already marketed products works for 
tobacco because the industry is well established.  Tobacco products have 
been marketed for hundreds of years, so there are standards to compare the 
new products to.
151
  Marijuana, on the other hand, is not legally sold in the 
United States, so there are no existing products to base a new product 
determination from.
152
  Since the FDA lacks the ability to compare new 
marijuana products to currently marketed products, the regulations 
requiring premarket approval for new marijuana products would not 
work.
153
  Nevertheless, a solution for premarket review of marijuana would 
require further research, because without premarket review marijuana 
would be less regulated then tobacco.
154
  Possible solutions that should be 
explored include prospective legislation that creates a predicate marijuana 
                                                          
 147.  See id. (providing limits to rule making as not to challenge tobacco’s 
recreational use).  
 148.  Compare § 387f (restricting rule promulgation authority to insure access) with 
§ 355 (requiring an extensive premarket approval process before a new drug can be 
marketed). 
 149.  See § 387j (defining tobacco products not marketed before February 15, 2007, 
or existing tobacco products that are modified as new tobacco products). 
 150.  See id. (comparing materials, ingredients, design, composition, heating source, 
and other features).   
 151.  See § 387j (2)(A)(i)(I) (exempting product that are substantially equivalent to 
traditional tobacco products from new product requirements).  
 152.  § 812 (placing marijuana in the Schedule I category of illicit drugs, and thus 
making it a Federal crime to sell marijuana in the United States). 
 153.  See § 387j (defining tobacco products not marketed before February 15, 2007, 
or existing tobacco products that are modified as new tobacco products). 
 154.  See id. (requiring new tobacco product, that are not substantially equivalent to 
predicate tobacco product, to undergo premarket review). 
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product once marijuana has been commercially marketed for a couple of 
years or a mandatory premarket review that is based on a new standard.
155
 
The drug model and tobacco model both provide viable regulation 
schemes that could be used to regulate marijuana.
156
  A drug model would 
provide the greatest control over marijuana, requiring thorough premarket 
review in order to demonstrate safety and effectiveness.
157
  Premarket 
review for a drug is very costly and time consuming, and ultimately may 
not result in approval.
158
  Additionally, the drug model would limit 
marijuana to medicinal use only, which would require people to obtain a 
prescription for lawful use, thereby restricting access.
159
  The tobacco 
model is in some ways like the drug model, providing regulation over 
manufacturing, labeling, advertising, and sale.
160
  However, the tobacco 
model would better handle the variety of marijuana strains by not requiring 
production to be limited to a single standardized product, unlike the drug 
model that requires one uniform product.
161
  The tobacco model would 
provide less control over marijuana, creating a balance between access and 
oversight by recognizing marijuana as a legal product, for adults, that poses 
potential health risks.
162
  Although the tobacco model would best 
accommodate the recreational use of marijuana, it would not be able to 
formally recognize valid medicinal uses of marijuana.
163
  Any claim from a 
manufacturer that its marijuana product could be used to treat or mitigate 
some condition would instantly make that marijuana product an 
                                                          
 155.  This comment recognizes that some degree of premarket review would be 
critical, however, the creation of a new premarket review exclusively for marijuana is 
outside the purview of this comment.  
 156.  See generally §§ 301 et seq. (providing statutes for the regulation of drugs and 
tobacco).  
 157.  See generally § 355 (requiring the sponsor of any new drugs to demonstrate 
safety and effectiveness through clinical trials before commercially marketing the 
product).  
 158.  See Herper, supra note 40 (explaining a single clinical trial can cost up to $100 
million).   
 159.  See § 353(b) (requiring drugs with potential safety issues be prescribed by a 
licensed practitioner). 
 160.  See generally § 387 (imposing regulations upon tobacco sales, advertising, 
labeling, and manufacturing). 
 161.  See BOTANICAL GUIDANCE, supra note 33, at 11-12 (recommending sponsor 
produce batch-to-batch consistency). 
 162.  See TCA Overview, supra note 49 (explaining a goal of tobacco regulation is 
to prevent use of a potentially harmful substance before fully understanding risks). 
 163.  See § 321(g) (stating that claims to mitigate, treat, or prevent disease makes a 
product a drug). 
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unapproved new drug.
164
  Regardless, physicians could still recommend a 
marijuana product for purposes of treatment, even if that product is not 
formally recognized for treating said condition.
165
  Nevertheless, the 
tobacco model provides enough regulation to minimize the risks marijuana 
may present, such as pulmonary disease and access for minors.
166
 The 
major difference between the drug model and tobacco model is that the 
tobacco model would provide explicit statutory language preventing FDA 
from issuing regulations that would greatly inhibit access to marijuana.
167
  
A tobacco model would allow for distribution similar to cigarettes or 
alcohol.
168
  Because tobacco is a botanical product, the tobacco model 
would better incorporate marijuana, allowing the inconsistencies and 
variations that the drug model is not meant to handle.
169
 
IV. CONCLUSION 
The majority opinion in the United States favors the legalization of 
marijuana.
170
  A significant number of states have legalized marijuana for 
medicinal use, and a growing number of states have legalized marijuana for 
recreational use.
171
  When the federal government decides to follow the 
majority and legalize marijuana to some degree, they will have various 
models of regulation to choose from.
172
  The drug model provides the best 
regime for marijuana if legalized purely for medicinal purposes.
173
  Even 
                                                          
 164.  See § 321(p) (stating that any drug without an approved NDA is a new drug). 
 165.  Cf. “Off-Label” and Investigational Use of Marketed Drugs, Biologics, and 
Medical Devices – Information Sheet, FDA, http://www.fda.gov/RegulatoryInformat
ion/Guidances/ucm126486.htm (last visited Dec. 5, 2014) (recognizing physicians 
ability to prescribe medicine for off-label uses). 
 166.  See § 387f (giving HHS Secretary authority to create rules promoting public 
health with regards to tobacco). 
 167.  See generally § 387f (d) (detailing restrictions on the Secretaries rule making 
authority). 
 168.  See id. (providing that face-to-face sales cannot be eliminated, nor can a 
prescription be required to by tobacco) 
 169.  See BOTANICAL GUIDANCE, supra note 33, at 2 (defining botanical product as a 
finished product that contains vegetable matter). 
 170.  See Swift, supra note 1 (discussing that 58% of Americans favor legalization 
of marijuana).  
 171.  See Marijuana Map, supra note 8 (showing 23 state and the District of 
Columbia have legalized marijuana).  
 172.  See generally §§ 301 et seq. (providing FDA with authority to regulate a 
variety of products accounting for about 25 cents of every dollar spent by consumers in 
the United States).  
 173.  See § 355 (requiring new drugs to be generally recognized as safe and effective 
my experts).  
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though marijuana would have difficulties obtaining an NDA due to 
standardization issues, the drug model’s safe and effective standard would 
ensure patients get the best marijuana product for treating their condition.
174
  
However, if recreational use of marijuana is legalized, then the tobacco 
model would be far superior, providing enough regulation to mitigate risk 
but maintain access to marijuana, while also avoiding standardization 
issues.
175
  Nevertheless, the current FDA regime could incorporate both 
models by allowing the tobacco model to regulate recreational use, while 
still affording manufacturers the opportunity to submit NDAs if they wish 
to make drug claims or have their products covered by insurance.
176
  
Current medical marijuana markets include different strains of marijuana 
that are supposedly better for particular conditions.
177
 A mature medical 
marijuana market almost certainly will not be one size fits all.
178
 Producers 
will want to customize their products and make claims promoting specific 
products for specific uses.
179
 The legalization of marijuana is coming and 
the FDA has the means to regulate its distribution.
180
 
 
                                                          
 174.  See BOTANICAL GUIDANCE, supra note 33, at 11-12 (recommending a single 
formulation and a single dosage form be used throughout different states of the clinical 
trials unless impossible). 
 175.  See TCA Overview, supra note 49 (explaining a goal of tobacco regulation is 
to prevent use of a potentially harmful substance before fully understanding risks). 
 176.  See MEDICARE DRUG COVERAGE UNDER MEDICARE PART A, PART B, PART C, 
& PART D, HHS (Jan. 2014), available at http://www.cms.gov/Outreach-and-
Education/Outreach/Partnerships/downloads/11315-P.pdf (requiring a medication to be 
FDA approved in order for Medicare Part D to cover it). 
 177.  See How Do You Know What Medical Marijuana Strain Is Right for You?, 
UNITED PATIENTS GROUP (Jan. 31, 2012), http://www.unitedpatientsgroup.com/bl
og/2012/01/31/how-do-you-know-which-medical-marijuana-strain-is-right-for-you/.  
 178.  Cf. Amanda Reiman, The Fallacy of a One Size Fits All Cannabis Policy, 35 
HUMBOLDT JOURNAL OF SOCIAL RELATIONS 104, 118 (2013), available at 
http://www2.humboldt.edu/hjsr/docs/fwhjsrparagraph/Issue%2035%20Seventh%20Art
icle%20Reiman.pdf (acknowledging that marijuana is a complex plant with many 
forms and uses).  
 179.  See, e.g., Strain Guide, MEDICAL MARIJUANA STRAINS, http://www.medica
lmarijuanastrains.com/strain-guide/ (last viewed Apr. 22, 2015) (creating a search 
index for medical marijuana based on illness and desired effect). 
 180.  See Swift, supra note 1 (finding that 58% of Americans favor legalizing 
marijuana). 
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